02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
00:04 , Oct 12, 2018 |  BC Innovations  |  Emerging Company Profile

Spinogenix’s Spine Craft

Spinogenix Inc. is developing small molecules for cognitive impairment in neurodegenerative diseases that rebuilds dendritic spines to reverse, not just halt, synaptic loss. CNS synapses that relay signals involved in memory and cognitive function are...
17:39 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting Rho kinase could help to treat AD. In primary rat cortical neurons stimulated with DKK1 to produce β amyloid, the Rho kinase inhibitor Eril...
17:59 , Aug 3, 2018 |  BC Week In Review  |  Company News

China Medical gains Chinese product rights in trio of deals

China Medical System Holdings Ltd. (HKSE:867) announced a series of deals in July under which it gained rights to several products in China, including Hong Kong, Macao and Taiwan. China Medical obtained exclusive rights from...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Basilea, Asahi Kasei Pharma deal

Basilea granted Asahi exclusive rights in Japan to develop and commercialize isavuconazole. Basilea will receive CHF7 million ($7.2 million) up front and is eligible for up to CHF60 million ($61.6 million) in milestones, plus double-digit...
07:00 , Jun 23, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: In vitro system to preserve muscle stem cell quiescence pre-transplant and regenerative potency post-transplant

Drug platforms TECHNOLOGY: Cell therapy An artificial in vitro niche could help preserve muscle stem cell quiescence before transplant to enhance regenerative potency after transplant. The niche consisted of engineered artificial muscle fibers composed of...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Company News

Array BioPharma, Asahi Kasei Pharma deal

Array granted Asahi exclusive rights in Japan, Korea, Taiwan and China to commercialize and develop ARRY-954 and other select neurotrophic tyrosine kinase receptor 1 ( TrkA ; NTRK1 ) inhibitors to treat pain, inflammation and...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Asahi Kasei Pharma, RaQualia deal

Asahi and RaQualia partnered to discover pain compounds targeting an undisclosed ion channel. The partners will use RaQualia’s drug development technology. RaQualia will receive an undisclosed research collaboration payment and will be eligible for undisclosed...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Microtubule-associated protein τ (tau; MAPT; FTDP-17); Rho-associated coiled-coil containing protein kinase 1 (ROCK1); ROCK2

Neurology INDICATION: Progressive supranuclear palsy (PSP) Patient sample and fruit fly studies suggest ROCK1 or ROCK2 inhibitors could help treat PSP and corticobasal degeneration (CBD), which is caused by neuronal accumulation of a four-repeat isoform...